Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1204

Shown on this page

Current sort

Live official records

Conditions: HCC
Interventions: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012; Biological · Device
Lead sponsor: Geneos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more

Conditions: Multiple Myeloma
Interventions: Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 60
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more

Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions: XL092, Nivolumab; Drug
Lead sponsor: Karie Runcie; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 2 more

Conditions: Systemic Lupus Erythematosus
Interventions: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 22
States / cities: Vestavia Hills, Alabama • Chandler, Arizona • Mesa, Arizona + 19 more

Conditions: Multifocal Motor Neuropathy (MMN), MMN
Interventions: Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo, IVIg-placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 24
States / cities: Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
Interventions: Catheter ablation; Device
Lead sponsor: Heart Rhythm Clinical and Research Solutions, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more

Conditions: Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Interventions: Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide; Other · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more

Conditions: Friedreich's Ataxia
Interventions: Aerobic Exercise; Behavioral
Lead sponsor: Scott Barbuto; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Huntington Disease
Interventions: Votoplam (blinded), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 40
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 36 more

About this Columbia University Irving Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Columbia University Irving Medical Center

Filter and sort this campus

Live official records

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Cardiac Output and Fatigue in Friedreich's Ataxia

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

About this Columbia University Irving Medical Center institution page